Printer Friendly
The Free Library
19,585,946 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Amgen and Genentech Sign License Agreements For Antibody Patents.


THOUSAND OAKS, Calif. & SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif. -- Amgen (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:AMGN) and Genentech Inc. (NYSE NYSE

See: New York Stock Exchange
:DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
) today announced that they have entered into license agreements granting licenses to each other under multiple patents relating to the manufacture and use of antibodies and related technology. These agreements include a grant by Genentech to Amgen of a license for multiple antibodies under the Cabilly patent family (U.S. Patent No. 6,331,415 et al.) relating in part to methods of producing immunoglobulins.

Financial details of the license agreements were not disclosed.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease Kidney Disease Definition

Kidney disease is a general term for any damage that reduces the functioning of the kidney. Kidney disease is also called renal disease.
, rheumatoid arthritis rheumatoid arthritis

Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course.
, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

About Genentech

Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange New York Stock Exchange (NYSE)

World's largest marketplace for securities. The exchange began as an informal meeting of 24 men in 1792 on what is now Wall Street in New York City.
 under the symbol DNA. For additional information about the company, please visit http://www.gene.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:Amgen and Genentech Sign License Agreements For Antibody Patents.
Publication:Business Wire
Geographic Code:1USA
Date:Jan 26, 2006
Words:280
Previous Article:Wilshire Bancorp Increases Net Income 50% in Fourth Quarter of 2005 and 43% in Full Year; Record Year Fueled by Strong Growth and Marked by Excellent...
Next Article:LaBarge, Inc. Reports Financial Results for Fiscal 2006 Second Quarter; Second-Quarter Results are Consistent with the Company's Guidance; Backlog...
Topics:



Related Articles
Of judges, genes and genetic engineers: biotech attorneys approach the bench.
Genentech CEO Says Amgen/TKT Trial Outcome Not a Bellwether for Biotech; Broader Issue of Gene Patents Addressed at Congressional Hearings This Week.
AMGEN KILLS DEAL FOR LYMPHOMA DRUG.
CAMBRIDGE ANTIBODY TECHNOLOGY/AMGEN RESTRUCTURE AGREEMENT.
Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement.
AMGEN SWINGS FOR THE FENCES INVESTORS BIT COOL TO HIGH R&D PRICE.
Affitech Renews Exclusive Worldwide Phage Display License From DKFZ; 'Breitling' Patents Hold Key Position in Human Antibody Discovery Field.
sanofi-aventis Licenses Broader Access to ImmunoGen's Antibody Humanization Technology.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles